| Date Filed | Type | Description |
| 10/10/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/05/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 09/28/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 08/17/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 20% stake in Neoleukin Therapeutics, Inc. |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/27/2023 |
SC 13D
| Redmile Group, LLC reports a 6.6% stake in NEOLEUKIN THERAPEUTICS, INC. |
| 07/19/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/18/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 07/18/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 07/18/2023 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Agreement and Plan of Merger, by and among Neoleukin Therapeutics, Inc., Project North Merger Sub, Inc. and Neurogene Inc",
"Form of Contingent Value Rights Agreement",
"Form of Neurogene Support Agreement",
"Form of Neoleukin Support Agreement",
"Form of Lock-Up Agreement",
"Letter Agreement, by and between Neoleukin Therapeutics, Inc. and Baker Bros. Advisors LP",
"NEUROGENE AND NEOLEUKIN ANNOUNCE DEFINITIVE MERGER AGREEMENT",
"Investor Presentation, dated July 2023" |
|
| 06/12/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/20/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/20/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
| 03/08/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/03/2023 |
SC 13G
| PICTET ASSET MANAGEMENT SA reports a 0% stake in Neoleukin Therapeutics Inc. |
| 01/23/2023 |
8-K/A
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 01/19/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/30/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/30/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 10/31/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
| 07/27/2022 |
8-K
| Regulation FD Disclosure Interactive Data |
| 07/19/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/15/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|